Selected publications of the first funding period at a glance
PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement.
- Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7
- Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1
- Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2
- Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z
- Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1
- Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7
- Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7
- Velasco Cárdenas RM et al. Nature Immunol 2023 doi: 10.1038/s41590-023-01658
- Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x
- Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082
- Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675.
- Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460.
- Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014
- Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553
- Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004
- Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022.
- Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0.
- Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004.
- Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672.
- Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419.
- Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012.
- Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4.
- Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015.
- Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005
- Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6
Publications based on CRC1479 funding
Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Boerries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021 Dec 20;19(1):123. doi: 10.1186/s12964-021-00801-3.
Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. Epub 2021 Dec 13.2021
El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021 Nov 8;12(1):6436. doi: 10.1038/s41467-021-26683-0.
Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O’Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021 Oct 28;184(22):5577-5592.e18. doi: 10.1016/j.cell.2021.09.022. Epub 2021 Oct 12.2021.
Bernasconi R, Thriene K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth AC, Stumpe M, Kiritsi D, Martin SF, Hinz B, Bruckner-Tuderman L, Dengjel J, Nyström A. 2021. Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7). EMBO Mol Med. 2021 e14392. doi: 10.15252/emmm.202114392.
Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer.
Nat Rev Cancer. 2021 Sep;21(9):541-557. doi: 10.1038/s41568-021-00383-9.
